Jason Liang, DPM
Foot & Ankle Surgery · Tulsa, OKNPI 1003235250
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Elite Orthopedics, LLC at 32.6% of the total. Reporting peaked in 2022 at $5,199 and has fallen 72.5% since, to $1,430 in 2025.
Across 123 payments — averaging $100.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elite Orthopedics, LLC$4K
- Arthrex$3K
- Treace Medical Concepts, Inc.$2K
- Stryker$1K
- Paragon 28, Inc.$325
- Johnson & Johnson$303
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$2,00016%
- Travel & lodging$2,30519%
- Food & beverage$4,35435%
- Education$3,60029%
- Gifts$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elite Orthopedics, LLC | 18 | $4,029 |
| Arthrex | 6 | $3,395 |
| Treace Medical Concepts, Inc. | 17 | $1,625 |
| Stryker(2 entities) | 21 | $1,382 |
| Paragon 28, Inc. | 4 | $325 |
| Johnson & Johnson(2 entities) | 8 | $303 |
| Paratek Pharmaceuticals, Inc. | 7 | $226 |
| Abbott | 1 | $179 |
| Integra Lifesciences Corporation | 6 | $97 |
| Polynovo North America LLC | 2 | $72 |
| Pylant Medical | 2 | $70 |
| AbbVie | 4 | $65 |
| Bioventus LLC | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $56 |
| Reprise Biomedical, Inc. | 2 | $53 |
| KCI USA, Inc. | 3 | $52 |
| Mimedx Group, Inc. | 1 | $51 |
| Nalu Medical, Inc. | 1 | $41 |
| Solventum Corporation | 1 | $36 |
| Medline Industries LP | 1 | $35 |
| Organogenesis Inc. | 2 | $34 |
| Smith+Nephew | 2 | $29 |
| Averitas Pharma Inc. | 1 | $29 |
| P Bar Medical LLC | 1 | $24 |
| Vertex | 1 | $23 |
| Kerecis Limited | 1 | $21 |
| Novo Nordisk | 1 | $15 |
| Pfizer | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$953
- INBONE$393
- ESPRIT$179
- INFINITY ADAPTIS$174
- LAPIPLASTY SYSTEM 1$156
- NUZYRA$117
- PSI IMPLANTS$111
- XARELTO$104
- TTC NAIL$104
How this compares
$12,355 in reported general payments places this provider in the 80th percentile of 71 foot & ankle surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 17 | $230 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $211 |
| Meloxicam | 43 | $140 |
| Prednisone | 36 | $117 |
| Gabapentin | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Tulsa
- Wesley StotlerTulsa$268K
- Andronica HandieTulsa$149K
- Brandon KitchensTulsa$19K
- James DaviesTulsa$15K
- Nathan LashleyTulsa$6K
- Carl MillerTulsa$4K
- Abdurrahman KabaniTulsa$4K
- David StollerTulsa$3K
- Lateef LawalTulsa$1K
- Jill Jackson-SmithTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.